-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3150 Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Clinical Research, CML, Chronic Myeloid Malignancies, Diseases, Adverse Events, Myeloid Malignancies, Study Population, Human
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Philippe Rousselot, MD PhD1*, Jean-Christophe Ianotto, MD, PhD, HDR2*, Philippe Quittet, MD3*, Maya Hacini4*, Gabrielle Roth-Guepin, MD5*, Mathieu Meunier6*, Frederic Maloisel7*, Valérie Coiteux8* and Gabriel Etienne, MD, PhD9*

1Centre Hospitalier de Versailles; Université Versailles Paris-Saclay, Versailles, France
2Hematology department, Centre Hospitalier Universitaire de Brest, Brest, France
3Hematology department, CHU Montpellier, Hôpital Saint Eloi, Montpellier, France
4Centre Hospitalier de Chambéry, Chambéry, France
5Department of Clinical Hematology, CHRU Nancy, Vandoeuvre Les Nancy, France
6Department of Hematology CHU Grenoble Alpes, Grenoble, France
7Strasbourg Oncologie Libérale, Sainte-Anne non-profit Clinic, Rue Philippe Thys, 67000, Strasbourg, France
8Centre Hospitalier Universitaire, Lille, France
9Hematology, Institut Bergonié, Bordeaux, France

Background: Bosutinib (BOS) is approved in France for the treatment of newly diagnosed Philadelphia chromosome–positive (Ph+) chronic phase chronic myeloid leukemia (CML), and for patients (pts) with Ph+ CML previously treated with ≥1 tyrosine kinase inhibitor (TKI) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Aims: This study aimed to characterize the safety and effectiveness of BOS in pts with previously treated CML receiving treatment in a real-world clinical setting in France.

Methods: BOSEVAL is a non-interventional, observational, prospective study conducted at 23 centers in Metropolitan France. Eligible pts, aged ≥18 yr, had a diagnosis of Ph+ and/or BCR::ABL1+ CML and were resistant/intolerant to prior treatment with ≥1 TKI. Primary outcomes measures were treatment-related adverse events (TRAEs) and permanent BOS discontinuation due to TRAEs, as determined by the investigator.

Results: This study included 142 pts who commenced BOS treatment between Oct 22, 2015, and Dec 19, 2019, with a follow-up period of 3 yr from BOS initiation. Among the 139 pts evaluable for effectiveness, the median age at BOS initiation was 65.0 (range, 23.0−88.0) yr, 56.1% were male; 46.0%, 30.2% and 23.7% of pts received BOS as 2nd, 3rd, and ≥4th line treatment, respectively. Median time from CML diagnosis to the initiation of BOS treatment was 3.9 (range, 0.2−29.2) yr. In all, 64.7% of pts switched to BOS due to intolerance to their last TKI therapy; most common (≥20%) TKI therapies prior to BOS initiation were imatinib (46.8%) and dasatinib (33.1%).

At study completion (median follow-up, 3.1 yr), 55.6% of pts were still receiving BOS; median duration of treatment was 2.8 (range, 0−3.4) yr. Median dose at treatment initiation was 200 (range, 100−500) mg/day, and the average dose during treatment was 300 (range, 57−500) mg/day. Dose escalations were reported in 76.1% of pts. Dose reductions and dose interruptions occurred in 50.0% and 43.7% of pts, respectively. Most common primary reasons for permanent BOS discontinuation were intolerance (27.5%) and loss of response/suboptimal response (11.3%).

Adverse events (AEs) were reported in 99.3% of pts; 60.6% of patients experienced at least one serious AE and 88.0% of patients experienced TRAEs. Most common (≥10%) any grade TRAEs were diarrhea (53.5%), hepatocellular injury (14.8%), nausea (14.1%) and abdominal pain (10.6%). TRAEs led to permanent treatment discontinuation in 26.8% of pts; the most common (≥2%) were diarrhea, pleural effusion, hepatocellular injury, increased aspartate/alanine aminotransferase and vomiting in 7.7%, 4.9%, 4.9%, 2.8% and 2.1% of patients, respectively. BOS cross-intolerance was reported in 7 pts; cross-intolerance due to recurrence of pleural effusions was reported in 3 dasatinib-intolerant pts and 1 dasatinib and imatinib-intolerant pt, cross-intolerance due to cardiac failure, pain or diarrhea was reported in 3 imatinib-intolerant pts.

Among the 139 pts, evaluable for effectiveness, 70.5% attained or maintained molecular responses at any time on treatment (MMR, 15.1%; MR4, 10.1%; MR4.5, 15.8%; MR5, 29.5%). Among responders, the Kaplan-Meier probability of maintaining a molecular response at 3 yr was 81% (95% CI, 72–88). On-treatment transformations to accelerated and blast phase occurred in 3 (2.2%) pts and 1 (0.7%) pt, respectively. The Kaplan-Meier estimated progression-free and overall survival rates at 3 yr were 93% (95% CI, 87−96) and 95% (95% CI, 89−97), respectively. During the study, 7 deaths occurred; 2 were considered related to CML and 1 was TRAE (pneumonia) per investigators.

Conclusions: This real-world analysis characterized the safety and effectiveness of BOS in previously treated pts with CML in France.

Disclosures: Rousselot: Pfizer: Consultancy; Incyte: Consultancy. Ianotto: GSK: Membership on an entity's Board of Directors or advisory committees. Quittet: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Meunier: Novartis: Consultancy; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alexion: Consultancy; BMS: Membership on an entity's Board of Directors or advisory committees; GSK: Speakers Bureau.

*signifies non-member of ASH